Banco BTG Pactual’s Ocular Therapeutix OCUL Stock Holding History

Banco BTG Pactual’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,256	Closed	-$63K	–	66
2017 Q3	$63K	Buy	+10,256	New	+$66K	0.03%	70

Other funds holding OCUL

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Banco BTG Pactual's OCUL Position: Q4 2017 in Review

Banco BTG Pactual sold out of Ocular Therapeutix (OCUL) in Q4 2017, closing a stake of 10,256 shares — an estimated $63K sold.

Banco BTG Pactual first reported a position in OCUL in Q3 2017 and held it in 1 quarter. The position peaked at $63K in Q3 2017. 69 funds tracked by Wall St. Rank hold OCUL as of Q4 2017.

Banco BTG Pactual reported no remaining Ocular Therapeutix position as of Q4 2017 after selling out during the quarter.
Banco BTG Pactual sold 10,256 Ocular Therapeutix shares in Q4 2017, an estimated $63K.
Banco BTG Pactual first reported a position in Ocular Therapeutix in Q3 2017 and held it in 1 quarter.
Banco BTG Pactual's Ocular Therapeutix position peaked at $63K in Q3 2017.
69 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2017.

Based on Banco BTG Pactual's 13F filing for Q4 2017, filed 9 Feb 2018.